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Caroli’s disease belongs to a group of hepatic ﬁbropolycystic diseases and is a hepatic manifestation of autosomal recessive
polycystic kidney disease (ARPKD). It is a congenital disorder characterized by segmental saccular dilatations of the large
intrahepatic bile duct and is frequently associated with congenital hepatic ﬁbrosis (CHF). The most viable theory explaining
its pathogenesis suggests that it is related to ductal plate malformation. The development of the polycystic kidney (PCK)
rat, an orthologous rodent model of Caroli’s disease with CHF as well as ARPKD, has allowed the molecular pathogenesis
of the disease and the therapeutic options for its treatment to be examined. The relevance of the ﬁndings of studies using
PCK rats and/or the cholangiocyte cell line derived from them to the pathogenesis of human Caroli’s disease is currently
being analyzed. Fibrocystin/polyductin, the gene product responsible for ARPKD, is normally localized to primary cilia, and
defects in the ﬁbrocystin from primary cilia are observed in PCK cholangiocytes. Ciliopathies involving PCK cholangiocytes
(cholangiociliopathies) appear to be associated with decreased intracellular calcium levels and increased cAMP concentrations,
causing cholangiocyte hyperproliferation, abnormal cell matrix interactions, and altered ﬂuid secretion, which ultimately result in
bile duct dilatation. This article reviews the current knowledge about the pathogenesis of Caroli’s disease with CHF, particularly
focusing on studies of the mechanism responsible for the biliary dysgenesis observed in PCK rats.
1.Introduction
Caroli’s disease belongs to a group of hepatic ﬁbropolycystic
diseases [1, 2]. It is a congenital disorder characterized by
a biliary abnormality consisting of segmental saccular dila-
tations of the large intrahepatic bile duct. It is frequently
associated with varying degrees of portal ﬁbrosis, correspo-
nding to congenital hepatic ﬁbrosis (CHF). Caroli initially
described two variants of the biliary abnormality with and
without CHF (Caroli’s syndrome and Caroli’s disease), and
the form without CHF is quite rare.
A signiﬁcant proportion of Caroli’s disease cases involv-
ing CHF are transmitted in an autosomal recessive manner
andareassociatedwithautosomalrecessivepolycystickidney
disease (ARPKD). The incidence of ARPKD is 1 in 20,000
live births [3]. Renal failure may be present at birth, and the
disease presentation is not limited to the neonatal period;
it can be diagnosed in childhood or even adolescence or
adulthood [4]. These late-presenting cases typically display
less severe kidney disease, but more commonly involve liver
disease complications.
Caroli’s disease is a developmental anomaly, and the
most viable theory explaining its pathogenesis is that it is
related to ductal plate malformation at diﬀerent levels of the
intrahepatic biliary tree [5]. Intrahepatic bile ducts develop
from bipotential liver progenitor cells that are in contact
with the mesenchyme of the portal vein, which form from
the ductal plates [6]. The ductal plates are then remodeled
into mature tubular ducts. The ductal plate remodeling
processbegins fromthelargerductstothesmallerperipheral
ducts. The heredity factors causing Caroli’s disease can exert
their inﬂuence not only during the early embryological
period in which large intrahepatic duct formation occurs,
but also during the later development of the more proximal
interlobular ducts involved in CHF.
The molecular pathogenesis of Caroli’s disease is incom-
pletely understood. Human and experimental data have sug-
gested several potential mechanisms that could lead to cyst2 International Journal of Hepatology
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Figure 1: The liver of a Caroli’s disease patient with CHF. Multiple cystic dilatations of the intrahepatic bile ducts are grossly (a) and
histologically (b) visible. Hematoxylin-eosin staining (b).
formation in ﬁbropolycystic liver diseases including those
of Caroli’s disease patients: (i) increased cell proliferation
and apoptosis; (ii) enhanced ﬂuid secretion; (iii) abnormal
cell-matrix interactions; (iv) alterations in cell polarity; and
(v) abnormal ciliary structure or function [7]. To study the
cyst pathogenesis of ARPKD, diﬀerent experimental animal
models including cpk, bpk, and orpk mice and several types
of knockout mice have been used [8–12]. Among them,
the polycystic kidney (PCK) rat is an orthologous model
of ARPKD that represents the phenotype of the slowly
progressive form of ARPKD and is also a novel animal model
of Caroli’s disease with CHF [13].
This article reviews our current knowledge of the patho-
genesis of Caroli’s disease with CHF, particularly focusing
on studies about the mechanism responsible for the biliary
dysgenesis observed in the PCK rat. First, the clinicopatho-
logical and genetic aspects of Caroli’s disease with CHF are
described. In the following section, Caroli’s disease refers to
the form of the disease associated with CHF, since Caroli’s
disease without CHF is rare.
2.Caroli’sDisease
2.1. Clinical Features. Renal involvement is encountered in
up to 60% of patients with Caroli’s disease [14]. Hepatic
manifestations of ARPKD are present in 15–45% of patients
and include an enlarged liver, portal hypertension, or
abnormal ﬁndings on hepatic imaging [15]. A few rare cases
of Caroli’s disease have occurred in the setting of autosomal
dominant polycystic kidney disease (ADPKD) [16].
The clinical manifestations of Caroli’s diseases are related
to both biliary abnormalities and portal hypertension due to
CHF [14, 17, 18]. Its clinical progression and presentation
are highly variable, and symptoms may appear late in life.
Bile ducts dilatation induces a predisposition to bile
stagnation, leading to the formation of lithiases. Bacterial
cholangitis occurs frequently and may be complicated by
hepatic abscess formation and sepsis. Recurrent cholangitis
dominates the clinical course and is the principal cause of
morbidity and mortality. After cholangitis occurs, a large
number of patients die within 5–10 years [14]. Secondary
biliary cirrhosis can occur due to biliary obstruction.
Portal hypertension due to CHF may lead to ascites
and esophageal variceal hemorrhaging. Splenomegaly and
hepatomegaly are common. Children with Caroli’s disease
usually display earlier symptom onset and a more rapidly
progressive disease because of the combined eﬀects of
cholangitis and portal hypertension.
Caroli’s disease may progress to cholangiocarcinoma.
The occurrence of cholangiocarcinoma has been reported in
7–14% of patients [19]. A rare case of cholangiocarcinoma
arising in CHF has also been reported [20].
The laboratory ﬁndings of Caroli’s disease are nonspeci-
ﬁc. Transaminase levels may be slightly elevated. A complete
blood count might reveal thrombocytopenia and leukopenia
if portal hypertension and hypersplenism are present. An
elevated white blood cell count and increased serum alkaline
phosphatase or direct bilirubin levels could indicate cholan-
gitis. BUN and creatinine values should also be measured to
detect any associated renal disease.
2.2. Pathology. The biliary abnormalities of Caroli’s disease
are characterized by progressive and segmental saccular or
cystic dilatation of the intrahepatic bile duct (Figure 1).
The disease might be limited to one lobe of the liver,
most commonly the left lobe. Histologically, the dilated
ducts are lined by the biliary epithelium, which may be
hyperplastic and ulcerated. In patients with cholangitis, an
acute and chronic inﬂammatory cell inﬁltrate is seen around
the dilated bile ducts. In the presence of CHF, dense portal
ﬁbrosis is observed, and the ﬁbrotic region often contains
variable numbers of abnormally shaped bile ducts and
hypoplastic portal vein branches. The hepatic parenchyma is
subdivided by the overgrowth of portal ﬁbrous tissue, while
noparenchymalregenerativeactivityisevident,whichallows
the condition to be diﬀerentiated from cirrhotic regenerative
nodules.
The mechanism of the development of cholangiocarci-
noma in Caroli’s disease remains unclear. In chronic biliary
diseases, it has become evident that cholangiocarcinomaInternational Journal of Hepatology 3
arising in the large bile ducts undergoes a multistep carcino-
genic process, and biliary intraepithelial neoplasia (BilIN)
is considered to be the precursor lesion [21]. BilIN is
frequently seen in patients with hepatolithiasis, and it can be
encountered in the livers of Caroli’s disease patients. Biliary
papillomatosis has also been observed in Caroli’s disease
[22]. Thus, cholangiocarcinoma in Caroli’s disease probably
arises despite a multistep carcinogenic process that is closely
related to chronic epithelial damage.
2.3. Pathological Studies. There is limited data available
from pathological molecular studies using human liver
tissues from patients with Caroli’s disease and/or CHF.
Cholangiocytes from the livers of patients with Caroli’s liver
have been shown to overexpress vascular endothelial growth
factor (VEGF), its receptors (VEGFR-1 and VEGFR-2), and
angiopoietin-2 [23]. VEGF expression on cholangiocytes
positively correlates with microvascular density around the
bile ducts, suggesting that it has a proliferative eﬀect on
cholangiocyte growth by inducing the production of an
abundantvascularsupply.VEGFmayalsostimulatebileduct
dilatation through the induction of cholangiocyte prolifera-
tion via an autocrine eﬀect [24]. In addition, the activation
of the mammalian target of rapamycin (mTOR) pathway
has been implicated in the overgrowth of cholangiocytes in
Caroli’s disease [25].
Cholangiocyte overgrowth is linked to abnormalities in
cell cycle progression and also to microRNA expression.
The progression of cells through the cell cycle is controlled
by a family of dual speciﬁcity phosphatases, Cdc25, that
activate cyclin-dependent kinases. The biliary epithelium of
CHF overexpresses Cdc25A protein (an isoform of Cdc25),
whichisaccompaniedbythedownregulationofamicroRNA
(miR15a) [26].
Around intrahepatic bile ducts, basement membrane
components such as laminin and type IV collagen, the major
basal laminar components are degraded in Caroli’s disease
[27]. These ﬁndings indicate that the reduction of laminin
and type IV collagen expression in the basement membrane,
a supportive structure of intrahepatic bile ducts exacerbates
theobservedbileductdilatation.Thedegradationoflaminin
and type IV collagen around bile ducts is also observed in
foci of cholangiocarcinoma in situ arising in Caroli’s disease,
indicating that once cholangiocarcinoma in situ develops in
the biliary epithelia of Caroli’s disease patients, it tends to
transform into invasive carcinoma [27].
In most types of chronic liver disease, activated hepatic
stellate cells play major roles in hepatic ﬁbrosis. However,
necroinﬂammatory changes and the activation of hepatic
stellate cells are not as marked in CHF as those seen in
ordinarychronicliverdiseasessuchaschronicviralhepatitis.
The fact that abundant connective tissue growth factor
(CTGF) is retained by heparin sulfate proteoglycans (HSPG)
in the ﬁbrous portal tracts could be responsible for the
unresolved hepatic ﬁbrosis observed in CHF [28]. Portal
mononuclear cells and endothelial cells expressing CTGF
and/or HSPG tend to collect around proliferated bile ducts
in CHF, providing a possible explanation for the mechanism
of the ﬁbrosis that characterizes CHF.
Figure 2: Dynamic CT reveals multiple cystic dilatations of the
intrahepatic bile ducts in a patient with Caroli’s disease with CHF.
The arrows indicate the central dot sign.
2.4.Diagnosis. Caroli’sdiseaseisdiagnosedbyimagingstud-
ies showing nonobstructive, saccular, or fusiform dilatations
of the intrahepatic bile ducts [29–31]. Ultrasonography
and endoscopic retrograde cholangiopancreatography are
the traditional methods of diagnosis. However, magnetic
resonance cholangiopancreatography is emerging as the
most useful diagnostic modality. On sonography, Caroli’s
diseasepresentsasintrahepaticcysticanechoicareasinwhich
ﬁbrovascular bundles and linear bridges or septa may be
present. The ﬁbrovascular bundles are composed of the
portal veins and hepatic arteries, which can be demon-
strated by Doppler ultrasonography and are recognized as
the central dot sign on CT with contrast enhancement
(Figure 2). Overlapping imaging ﬁndings are often detected,
which reﬂect its underlying pathology and associated com-
plications, including ﬁbrosis, ductal dilatation, cholangitis,
lithiasis, and malignancy [32]. A liver biopsy is rarely
required to make a diagnosis of Caroli’s disease.
2.5. Treatment. Treatment for Caroli’s disease is largely
supportive and is directed toward treating the biliary infec-
tion and complications associated with portal hypertension
[15]. Cholangitis, hepatic abscesses, and sepsis should be
treated aggressively with appropriate antibiotics. Infections
are particularly diﬃcult to eradicate in the presence of
bile stasis and intrahepatic lithiasis. Recurrent bouts of
cholangitis can lead to end-stage liver disease.
Common bile duct stones may require endoscopic
sphincterotomy and stone extraction, while the extraction
of intrahepatic stones is diﬃcult. Partial hepatectomy may
be curative when the disease is conﬁned to a single lobe of
the liver [33]. Ursodeoxycholic acid has been used to treat
intrahepatic lithiasis, which probably acts by increasing bile
ﬂow and decreasing bile stasis [34].
Variceal bleeding can be treated endoscopically with scle-
rotherapy or band ligation. A selective shunting procedure
can provide relief from the complications associated with
portal hypertension.4 International Journal of Hepatology
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Figure 3: The liver of a PCK rat. The gross (a) and histological (b) appearance of the adult rat liver closely resembles those of patients with
Caroli’s disease with CHF (Figure 1). Hematoxylin-eosin staining (b).
Liver transplantation is regarded as the ultimate treat-
ment for patients who suﬀer recurrent bouts of biliary
infection and those who also have complications related
to portal hypertension [35]. Patient survival is reported to
be excellent, and graft survival is comparable to or better
than that of patients who have received transplants for other
diseases [36]. Since the inheritance of the disease seems to
occur in an autosomal recessive manner, it is important to
provide genetic counseling to the patient’s family.
2.6. Genetics. ARPKD is caused by mutations in a single
gene, PKHD1, which has been localized to chromosome
6p21.1-p12. The gene consists of 86 exons and has a number
of alternatively spliced transcripts. Its longest open reading
frame contains 67 exons, which encode a 4074 amino acid
p r o t e i nc a l l e dﬁ b r o c y s t i no rp o l y d u c t i n[ 37, 38].
PKHD1 exhibits a high level of allelic heterogeneity, and
more than 300 mutations have been described throughout
PKHD1. A clear genotype/phenotype correlation has been
described in ARPKD, with two truncating mutations asso-
ciated with the most severe phenotype, while one or two
missensechangesareassociatedwithmilderdisease[39].The
genetic basis for the diﬀerences between ARPKD with and
without CHF has not been fully elucidated [40]. Mutations
in PKHD1 have also been identiﬁed in patients with Caroli’s
disease. PKHDL1, a homologous gene that is not involved in
renal cystic disease has also been described [41].
2.7. Fibrocystin/Polyductin. Fibrocystin is a receptor-like
membrane-associated protein. Structural predictions indi-
cate that it has a large extracellular region with multiple
copies of the TIG domain (an immunoglobulin-like fold),
a single transmembrane region, and a short cytoplasmic
tail. Based on its similarity with other TIG-containing
proteins such as the hepatocyte growth factor receptor MET,
ﬁbrocystin is suggested to function as a receptor or ligand,
since secreted forms can be generated from alternatively
spliced transcripts [42]. In addition, the promoter might be
directly regulated by hepatocyte nuclear factor-1β [43].
PKHD1 is preferably expressed in the kidneys with
lower levels observed in the liver, pancreas, and lungs [37].
Similarly, ﬁbrocystin is expressed in the cortical and
medullary collecting ducts of the kidney as well as the
biliary and pancreatic ducts [44], in which its distribution
is consistent with the disease’s phenotype. Fibrocystin is
localized to primary cilia as well as to the basal body of
epithelial cells and colocalizes with polycystin-2, the gene
product responsible for ADPKD [42, 45]. Fibrocystin is also
expressed in the normal ductal plate as well as in ductal plate
malformations including CHF and colocalizes with stem cell
m a r k e r si ns o m ed u c t a lp l a t ec e l l s[ 46].
Fibrocystin can undergo notch-like processing, resulting
in the release of the ectodomain from primary cilia [47].
Other studies have demonstrated cleavage of the ﬁbrocystin
ectodomain as well as the generation of a cytoplasmic frag-
ment that translocates to the nucleus [48]. Such proteolytic
cleavage can be elicited by the stimulation of intracellular
calcium release or protein kinase C activation. Fibrocystin
and polycystin-2 may act in a common molecular pathway
to regulate calcium responses in the epithelia [49]. The
structure and homologies of ﬁbrocystin suggest that it plays
a role in the regulation of cellular adhesion, repulsion, and
proliferation and/or the regulation and maintenance of renal
collecting tubules and bile ducts, but its exact role in normal
and cystic epithelia remains unknown.
3.The PCKRat
The PCK rat is derived from a Crj:CD (Sprague-Dawley) rat
strain, originating in Japan [50]. The polycystic disease it
suﬀers from is inherited in an autosomal recessive manner,
and this model has a spontaneous mutation in its Pkhd1
gene, an ortholog of human PKHD1 [37]. The model has
been rederived and is commercially available from Charles
River Laboratories (Wilmington, MA).
In the livers of PCK rats, multiple segmental and
saccular dilatations of the intrahepatic bile duct are observed
(Figure 3). In addition, ductal plate malformations are evi-
dentintheliversofPCKratfetuses(Figure 4),andtheductal
dilatation spreads throughout the liver and increases in
degree with age. The overgrowth of portal connective tissue
progresses after delivery. All of the gross and histologicalInternational Journal of Hepatology 5
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Figure 4: Ductal plate malformation in the fetal liver of a PCK rat. Compared with a normal fetal rat (a), dilatation of the ductal plate is
evident in the PCK liver (b, asterisks). Hematoxylin-eosin staining (a, b).
features of the PCK liver correspond to Caroli’s disease with
CHF.
To explore the mechanism of biliary dysgenesis suﬀered
by PCK rats, a cholangiocyte cell line has been developed
from the intrahepatic bile ducts of the PCK rat [51, 52].
The cholangiocytes of the PCK rat exhibit a higher rate of
proliferation,withadoublingtimeofapproximatelyhalfthat
of normal cholangiocytes, and maintain their biliary features
during passaging.
Hereafter, based on the results of studies using PCK rats
and/or the cholangiocyte cell line derived from them, the
recentdevelopmentsinourunderstandingofthecellularand
molecular pathogeneses of the biliary dysgenesis observed in
PCK rats are reviewed.
3.1. Proliferation and Apoptosis. Two key signaling pathways,
3 ,5 -cyclic adenosine monophosphate (cAMP) activated B-
Raf/MEK/ERK and AKT/mTOR/S6K/S6, have been impli-
cated in the increased proliferation of PCK cholangiocytes.
Epidermal growth factor (EGF) and its receptor (EGFR)
play important roles in promoting cholangiocyte prolifera-
tion. PCK cholangiocytes are hyperresponsive to EGF, and
the increase in their proliferation is accompanied by activa-
tion of the MEK5/ERK5 pathway [51]. The phosphorylation
of ERK1/2 is also increased in PCK cholangiocytes [53]. In
contrast to other mouse models of ARPKD, EGFR is not
overexpressed or mislocalized to the apical membrane in the
PCK cholangiocytes [51, 54].
The cAMP levels of the PCK cholangiocytes are also
increased [55]. These elevated cAMP levels stimulate cholan-
giocyte proliferation via downstream eﬀectors and exchange
proteins activated by cAMP (Epac1 and Epac2 isoforms) and
protein kinase A (PKA) [56]. Hyperproliferation of the PCK
cholangiocytes in response to PKA stimulation is associated
with decreased intracellular calcium levels, and the restora-
tion of calcium levels blocks PKA-dependent proliferation
via the PI3K/AKT pathway. In addition, PCK cholangiocyte
hyperproliferation is accompanied by the overexpression of
Cdc25A protein and the downregulation of miR15a [26,
57]. miR15a overexpression in PCKcholangiocytes decreases
Cdc25A levels, inhibits cell proliferation, and reduces cyst
growth, indicating a potential therapeutic strategy for the
disease.
The signaling pathway composed of AKT/mTOR/S6K/S6
is activated in PCK cholangiocytes (Ren XS et al., unpub-
lished data). In the PCK rat liver, apoptosis of the biliary
epithelium is less frequent than in normal rats until 1 week
after delivery but is more common than in normal rats at 3
weeksafterdelivery[13].Thus,dysregulatedcellkineticsmay
be involved in the biliary abnormalities associated with PCK
rats.
3.2. Fluid Secretion. Activated cAMP pathways can also lead
to increased ﬂuid secretion. Indeed, bile secretion is increa-
sed in the PCK rats compared with that in age-matched nor-
mal rats [58]. In normal cholangiocytes, the water channel
aquaporin-1, the chloride channel cystic ﬁbrosis transmem-
brane conductance regulator (CFTR), and the anion excha-
nger AE2 regulate ion-driven water transport. In PCK chola-
ngiocytes, aquaporin-1, CFTR, and AE2 are overexpressed
and show abnormal cellular localization, which could
account for their altered ﬂuid secretion [59].
3.3. Cell-Matrix Interactions. As is true in human Caroli’s
disease, the matrix proteins of the basement membranes
of the intrahepatic bile ducts are degraded in PCK rats,
and the biliary epithelium sits on the basement mem-
brane and displays abnormal decreases in laminin and
type IV collagen expression [27]. Since PCK cholangiocytes
overexpress plasminogen and the tissue-type plasminogen
activator, the generation of excessive amounts of plasmin
and the subsequent plasmin-dependent lysis of extracellular
matrix molecules may contribute to the progressive bile duct
dilatation observed.
3.4. Primary Cilia and Ciliopathies. Cholangiocytes are cil-
iated cells, and cholangiocyte cilia extend from the apical
plasma membrane into the bile duct lumen [60]. Cholan-
giocyte primary cilia are mechanosensory, osmosensory, and
chemosensory organelles that can detect changes in bile ﬂow
andosmolarityandtransducethemintointracellularsignals.
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elements via changes in intracellular calcium and cAMP
concentrations. Increased ﬂow causes a cilium-dependent
rise in intracellular calcium followed by a decrease in
the cAMP concentration via a calcium-inhibitable adenyl
cyclase.
In PCK rats, a splicing mutation in Pkhd1 results in
structural and functional ciliary abnormalities [61]. Fibro-
cystin is normally localized to primary cilia, whereas defects
in ﬁbrocystin from primary cilia are observed in PCK
cholangiocytes [62]. Defects in ciliary structure and their
integrated sensory/transducing functions appear to result in
decreased intracellular calcium and increased cAMP concen-
trations, causing cholangiocyte hyperproliferation, abnor-
mal cell-matrix interactions, and altered ﬂuid secretion.
These modiﬁcations can lead to abnormalities in biliary tree
diﬀerentiation, ultimately resulting in bile duct dilatation.
Other calcium channels such as Trpv4 are present in
cholangiocyte cilia, and the activation of Trpv4 leads to
increased intracellular calcium levels and reduces the hyper-
proliferative phenotype of PCK cholangiocytes [63].
In the liver, mutations in genes encoding ciliary-asso-
ciated proteins cause a broad spectrum of genetically hetero-
geneous disorders, which are referred to as ciliopathies [64].
Since cholangiocytes are the only epithelial cells in the liver
that possesses primary cilia, conditions aﬀecting the liver are
more appropriately called cholangiociliopathies [65].
3.5. Cholangitis. As PCK rats age, chronic suppurative
cholangitis becomes a frequent histologic ﬁnding [66].
Althoughtheclinicalsigniﬁcanceofcholangitisduetobiliary
infection is well recognized in Caroli’s disease, the impact
of biliary infection on its pathogenesis and progression is
poorly understood.
Lipopolysaccharides (LPS) induce VEGF expression in
PCK cholangiocytes via toll-like receptor 4 expressed on the
cells, which is accompanied by the activation of NF-κB( R e n
XS et al., unpublished data). Both LPS and VEGF increase
theproliferationofPCKcholangiocytes,suggestingthatLPS-
induced overexpression of VEGF in the biliary epithelium
leads to hypervascularity around the bile ducts, and con-
c u r r e n t l y ,L P Sa n dV E G Fa c ta sc e l lp r o l i f e r a t i v ef a c t o r sf o r
cholangiocytes.Thus,biliaryinfectionmayexacerbatebiliary
cystogenesis through the induction of VEGF in the biliary
epithelia of PCK rats.
Cholangitis is frequently associated with goblet cell
metaplasia of the biliary epithelium in PCK rats. LPS induces
upregulated CDX2 expression followed by aberrant mucus
core protein-2 expression via the activation of NF-κBi n
PCK cholangiocytes, which accounts for the development
of intestinal metaplasia in the setting of biliary infection
[66]. Although recurrent cholangitis probably leads to the
development of cholangiocarcinoma in some patients with
Caroli’s disease, we have not encountered the occurrence of
cholangiocarcinoma in PCK rats.
3.6. Hepatic Fibrosis. A mechanism similar to the epithelial-
mesenchymal transition (EMT) has been implicated in the
hepatic ﬁbrosis observed in PCK rats [67]. In PCK rat liver
sections, the intrahepatic bile ducts display two diﬀerent
phenotypes, bile ducts lined by cuboidal-shaped (C-type),
and ﬂat-shaped (F-type) cholangiocytes. The ﬂat-shaped
cholangiocytes (F-type) show reduced immunohistochemi-
cal expression of the biliary epithelial marker cytokeratin19
andpositiveimmunoreactivityforthemesenchymalmarkers
vimentin and ﬁbronectin. Treating PCK cholangiocytes with
transforming growth factor-β1( T G F - β1), a potent inducer
of EMT induces the expression of vimentin and ﬁbronectin
in vitro, indicating that PCK cholangiocytes acquire mes-
enchymal features in response to TGF-β1 and participate in
progressivehepaticﬁbrosisbyproducingextracellularmatrix
molecules.EMThasbeenalsoimplicatedinthepathogenesis
of interstitial ﬁbrosis in the kidneys of PCK rats [68].
In elderly PCK rats, suppurative cholangitis is a frequent
histological ﬁnding in C-type cholangiocytes, while F-type
cholangiocytes are not associated with suppurative cholangi-
tisaccompaniedbypolymorphonuclearleukocyteaccumula-
tion in their lumen [67]. In addition, F-type cholangiocytes
occasionally show a ﬁbrous scar-like appearance. Recent
studies have shown that the majority of dilated intrahepatic
bile ducts in PCK rats are initially connected to the biliary
tree but over time become separated from it, resulting
in true cyst formation [61]. It is speculated that F-type
cholangiocytes are derived from the bile ducts that have been
disconnected from the biliary tree, which may account for
the observation of true biliary cysts in PCK rats.
The renin-angiotensin system is upregulated in the livers
of PCK rats [69]. Angiotensin-converting enzyme (ACE)
and angiotensin II, as well as their downstream target, the
proﬁbrotic mediator TGF-β, are overexpressed in the PCK
liver, suggesting that the renin-angiotensin system activation
is another important mediator of hepatic ﬁbrosis.
3.7. Therapeutic Approaches. Understanding of the molec-
ular mechanisms of cyst formation and growth has led to
the discovery of novel potential therapeutic approaches for
ﬁbropolycystic diseases. However, in PCK rats, relatively few
therapeutic reagents are eﬀective for both liver and kidney
cystogenesis.
Octreotide, a somatostatin analogue known to inhibit
cAMP, decreases hepatic cyst volume, the hepatic ﬁbrosis
score,andmitotic indicesinthePCKliver,andsimilareﬀects
are observed in the kidneys [55]. Pioglitazone, a peroxisome
proliferator activator receptor gamma agonist, inhibits bile
duct dilatation and hepatic ﬁbrosis as well as renal cyst
growth, which is associated with decreased CFTR expression
and reduced cell proliferation [53, 70].
As another example of therapies that are eﬀective for
both liver and kidney lesions in PCK rats, the inhibition
of Src activity with SKI-606 ameliorates biliary ductal
abnormalities and renal cyst formation [71]. The eﬀects of
Src inhibition suggest that the Erb2 and B-Raf/MEK/ERK
pathways are involved in Src mediated signaling in ARPKD
and that this occurs without any reduction in cAMP levels.
The inhibition of renal cAMP production by treatment
with a vasopressin V2 receptor antagonist or by increasing
water intake to reduce plasma vasopressin decreases cell
proliferation and ameliorates kidney cystogenesis with an
associated reduction in B-Raf/MEK/ERK activity, leading toInternational Journal of Hepatology 7
improved renal function in PCK rats [72–74]. However, con-
sistent with the absence of the vasopressin V2 receptor in the
liver, it does not have a signiﬁcant eﬀect on ﬁbropolycystic
liver disease. Similarly, Trpv4 activation induces a signiﬁcant
decrease in renal cystic area but causes a nonsigniﬁcant
decrease in liver cyst formation [63].
ACE inhibition by chronic treatment with lisinopril
decreases proliferative and apoptotic pathways in the kid-
neys of PCK rats, resulting in improved kidney function
[75]. Chronic blockade of 20-hydroxyeicosatetraenoic acid
(HETE) with a speciﬁc inhibitor of the CYP4A and CYP4F
enzyme family prevents the formation of 20-HETE, resulting
in a signiﬁcant decrease in renal cyst formation in PCK rats
[76]. The activation of calcium-sensing receptors with R-568
reduces the interstitial ﬁbrosis, but not the cystogenesis, of
the PCK kidney [77]. However, it is unclear whether these
treatments, that is, the inhibition of ACE and 20-HETE
synthesis, and the activation of calcium-sensing receptors,
are eﬀective treatments for biliary dysgenesis in PCK rats.
Geﬁtinib,anEGFRtyrosinekinaseinhibitor,signiﬁcantly
improvesbiliarycystogenesisandhepaticﬁbrosisinPCKrats
but has no beneﬁcial eﬀects on renal cyst pathogenesis [78].
In addition, EGFR tyrosine kinase inhibition with EKI-785
and EKB-569 has no eﬀect on biliary dysgenesis in PCK rats,
and the kidney lesions are unaﬀected or rather worsened by
the treatment [54]. The inhibition of mTOR with sirolimus
does not attenuate the progression of liver or kidney disease
in PCK rats, which may be due to intrinsic or acquired
sirolimus resistance [79].
4. Conclusions
The development of PCK rats has allowed us to explore
the molecular pathogenesis of the disease and potential
therapeutic strategies for Caroli’s disease and ARPKD. The
relevance of ﬁndings obtained from studies using PCK rats
and/or the cholangiocyte cell line derived from them to the
pathogenesis of human diseases is currently being analyzed,
and several key signaling pathways have been elucidated. It
seems likely that future treatments for Caroli’s disease will
involve combination therapies aﬀecting several cystogenesis
pathways.
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